Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Levosimendan + dopamine in hypotensive heart failure
ChiCTR2000039714Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Sun Yat-sen University
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of levosimendan and dopamine in heart failure (HF) and heart failure with reduced ejection fraction (HFrEF) (2 arms), sponsored by The First Affiliated Hospital of Sun Yat-sen University. Primary endpoints: Incidence of major adverse cardiovascular events (MACE) and Improvement of cardiac function. Planned start Apr 2021; status: not yet recruiting.
02
Drugs
levosimendandopamine
03
Conditions
heart failure (HF)heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on ChiCTR2000039714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000039714.